Ovarian Cancer Research Alliance (OCRA), the world’s largest ovarian cancer charity, announced today the 2023 winners of the Rosalind Franklin Prize for Excellence in Ovarian Cancer Research and the Schreiber Research Prize for Outstanding Mentored Investigators. One recipient is being recognized for her noteworthy leadership in the field, which includes seminal work in novel therapeutics … Continued
Dr. Jasmine Plummer of St. Jude Children’s Research Hospital (formerly of Cedars-Sinai Medical Center) is a 2022 recipient of OCRA’s Early Career Investigator Grant. Her OCRA-funded project is focused on better understanding how genetic mutations trigger cancer development. The goal of her research is to find early biomarkers of ovarian cancer and also identify drugs to effectively … Continued
In an interview for the podcast Overlooked, OCRA’s President & CEO Audra Moran talked about the future of ovarian cancer research, and how Ovarian Cancer Research Alliance is harnessing the power of AI to advance discoveries. Read the Overlooked interview with OCRA’s Audra Moran. Listen to the Overlooked podcast episode “Genetics” featuring Sarah DeFeo, OCRA’s … Continued
Dr. Maria Victoria Botuyan of Mayo Clinic Rochester is a 2022 recipient of OCRA’s Early Career Investigator Grant. Her OCRA-funded research is focused on studying how several proteins function together in regulating the repair of DNA, with the aim of using this knowledge to help develop better ovarian cancer therapies over the long term. What … Continued
We took meaningful steps in the fight against ovarian and related gynecologic cancers this year, and we couldn’t have done it without your support. Join me for a look at this year’s most important updates, and please stand with us alongside patients, survivors and loved ones, with hope and commitment to a future without ovarian … Continued
Snap Summary: OCRA-funded researchers discovered a potential key to reducing chemotherapy resistance, and reducing recurrence rates for the most common type of ovarian cancer. A research team at Magee-Women’s Research Institute, University of Pittsburgh, made a breakthrough in the fight to tackle chemoresistance, a pervasive issue in ovarian cancer treatment. This groundbreaking study was led … Continued
Snap Summary: New findings could help develop better immune therapy for patients with the most common and lethal subtype of ovarian cancer. A recent study co-authored by Dr. Sherry Wu of The University of Queensland, Brisbane, and made possible in part by funding from OCRA, is making inroads toward immunotherapy as a viable option for … Continued
OCRA Announces Game-Changing Initiatives This month, OCRA announced a trio of initiatives that carry profound implications for ovarian cancer and related research and patient support: OCRA will expand its mission to include related gynecologic cancers, will create the first comprehensive ovarian and endometrial cancer registry, and will initiate a groundbreaking international data commons. Audra Moran, President and CEO of … Continued
Snap Summary: Research co-funded by OCRA found that foregoing genetic counseling before and after genetic testing does not negatively impact individuals who do not have a pathogenic mutation. Studies have shown that people who might have a hereditary cancer risk often do not get tested. This makes it important to identify needless barriers that may … Continued
Snap Summary: An OCRA-funded study sought to understand why certain ovarian cancer cells resist olaparib treatment, and discovered that introducing a second drug (mifepristone) while targeting certain cells (polyploid giant cancer cells) may offer a solution. In a study published in the journal Science Advances, researchers at MD Anderson Cancer Center set their sights on … Continued
A recent article from Stat News reports that as the United States continues to face a concerning shortage of vital chemotherapy drugs, ovarian cancer patients are among the hardest hit. According to Stat News, nearly 93% of U.S. cancer centers are reporting shortages of carboplatin, which is the most common first-line treatment for ovarian cancer. … Continued
Dr. Benjamin Bitler of the University of Colorado is a 2022 recipient of OCRA’s Collaborative Research Development Grant. His OCRA-funded project, which is expanding on findings from the Ovarian Cancer Research Group at the University of Colorado, aims to harness cutting-edge molecular profiling and advanced computational analysis in order to predict ovarian cancer recurrence and provide … Continued
Get email updates about research news, action alerts, and ways to join the fight.
